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SUCCESSFUL orthotopic liver transplan-tation provides a unique opportunity to 
study systemic effects of hepatic-based meta-
bolic disease and to potentially provide a cure 
for previously often fatal illnesses. From May 
9, 1981 through the next 12 months, 23 
patients received orthotopic liver transplants. 
Children ranged from 7.5 months to 18 years 
of age. Each patient re-::eived cyclosporin-A 
(CyA) and steroids. Eight of the 23 patients 
had identifiable metabolic disease, and 3 of 
the 8 had associated hepatic neoplasms. Seven 
of the 8 patients had evidence of correction of 
the underlying metabolic defect or showed 
clinical improvement. The eighth patient died 
prior to documenting correction of the defect. 
Metabolic indications for transplantation 
included: alpha-I-antitrypsin (AJA T) defi-
ciency (4), glycogen storage disease type I 
(GSD 1) (with adenomas) (1), herediatry 
tyrosinemia (with hepatocellular carcinoma) 
(1), Sea Blue Histiocyte syndrome (with 
hepatocellular carcinoma) (1), and Wilson's 
disease (I). Two of the 8 patients died. Each 
had AJAT deficiency. One died 6 weeks after 
transplant due to an hepatic' abscess, and the 
other died 3.5 months after transplant secon-
dary to a cerebral hemorrhage. 
Patients with AJAT deficiency are summa-
rized in Table 1. All patients had end-stage 
liver disease and/or severe portal hyperten-
sion. Three of the 4 patients had abnormally 
low levels of AJAT (2 with Pi ZZ and I with 
Pi SZ). Each of these 3 patients had periodic 
acid-Schiff stain positive and diastase-resis-
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tant granules in hepatocytes. A fourth patient, 
OT 226. had a normal AlA T level and was Pi 
MZ. Her liver did not demonstrate the char-
acteristic intracytoplasmic granules. Post-
transplant. 3 of the 4 patients had normal 
AJAT levels and. where measured. assumed 
the Pi type of the donor. OT 203 died prior to 
measuring his AlA T level and Pi type. Nota-
bly, the 2 patients who died had no evidence of 
granule accumulation in transplanted liver. 
GSD I was diagnosed in OT 218 after 
presenting with acidosis, hypoglycemia. 
growth failure. and hepatomegaly. She had a 
sibling who died of the same disease at 2.5 
years of age. At 8 years of age she underwent 
a portocaval shunt, which helped her growth 
but did not improve her hypoglycemia. She 
required frequent daytime feedings and con-
tinuous nocturnal nasogastric feedings. She 
developed progressive hepatomegaly, poor 
growth, and hepatic tumor nodules. She hem-
orrhaged into the tumor nodules, developed 
encephalopathy, and was transplanted in Feb-
ruary of 1982. 
Postoperatively she developed mild hyper-
glycemia that resolved within 48 hr. She 
maintained clinically normal glucose homeo-
stasis on 3 normal meals per day and no 
nocturnal feedings. Six weeks posttransplant, 
detailed carbohydrate metabolic studies con-
firmed a normal 24-hr fast, normal oral glu-
cose tolerance test, and a brisk response to 
parenterally administered glucagon. She is 
now leading a virtually normal life at home. 
Hereditary tyrosinemia, Fanconi's renal 
tubular disease, and rickets were diagnosed in 
OT 206 at I year of age. Strict dietary therapy 
normalized her serum amino acids and cor-
rected the renal defect with healing of her 
rickets. In July 1981 she was discovered to 
have hepatocellular carcinoma and developed 
progressive liver failure with markedly ele-
vated alpha-fetoprotein (AFP) levels. She was 
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Table 1. Liver Transplantation For Metabolic Disease 
Age 
Follow-up (Yearsl 
OT Sex Diagnosis Pretranspllll1t Posnranspllll1t Current Staws IMonths) 
192 10 a A,AT A,AT 44. Pi SZ A,AT 174 Pi MM Well. bili 0.6 13 
201 4a A,AT A,AT "LOW:' Pi ZZ A,AT"NL" Died 6 weeks,liver 
abscess 
203 18 a A,AT A,AT "LOW:' Pi ZZ A,A T NOT DONE" Died 31!z mo .. cerebral 
hemorrhage 
226 4~ A,AT A,AT 157 Pi ZZ A,AT85MM Well, bili 1.3 4 
218 16 ~ GSDI Nocturnal Feeds, Liver NL 24 hr fast, OGTT, Well. biliO.5 3 
Tumor. poor growth glucagon stimula-
tion 
206 O~ Tyrosinemia Cirrhosis, dietary ra- NL amino acids, ",FP, Well, bili 1.1 8 
striction, liver tu- regular diet, no tu-
mor. high ",FP mor 
222 79 Sea Blue Cirrhosis, neurodegen- No tumor. neurologic Well. bili 0.8 5 
Histiocyte eralive disorder. improvement 
liver tumor 
202 13 a Wilson's Ataxia. Cogwheel ri- Normal inteliect. mild Well. bili 0.7 Cu 99 10 
gidity. liver and bilateral foot drop Ilg/ dl ceruloplasmin 
renal failure. coma. 27 mg/dl 
Cu 651lg/ dl cerulo-
plasmin 4 mg/dl 
A,AT. alpha - 1 - antitrypsin (deficiency) (mg/dl); Pi. protease inhibitor type; NL. normal; BiIi, total bilirubin (mg/dl); GSD I, 
glycogen storage disease. type I; aFP. alpha fetoprotein; Cu. serum copper. normal 80-120 Ilg/dl; ceruloplasmin, normal 
20-40 mgidl; oral glucose tolerance test. 
transplanted on 11/13/81. Urine and plasma 
amino acids remained normal postoperatively 
without any dietary restriction, and her AFP 
levels fell to zero by 3 weeks after transplant. 
In addition. there has been no evidence of 
recurrent tumor. She has had problems of 
hypertension and rejection, both of which 
ha ve been controlled, and is now leading a 
virtually normal life. 
OT 222 was diagnosed as having a variation 
of the Sea-Blue Histiocyte syndrome in 
November 1981 after evaluation for pro-
gressive hepatic disease and a degenerative 
neurologic disorder. Hepatosplenomegaly was 
discovered at 2-3 months of age, and evalua-
tion for an etiology was unfruitful. Liver 
enzymes were twice normal. Bone marrow 
and ophthalmologic exams were normal. 
Liver biopsy at 5 months of age demonstrated 
cirrhosis without cholestasis. She had a single 
myoclonic seizure at that time. She developed 
normally until 5 years of age when parents 
noted an unsteady gait, tremor, and a paresis 
of upward gaze. She had hyperactive deep 
tendon reflexes. mild hypertonicity, dysdiado-
chokinesia, extensor plantar reflexes, mild 
truncal ataxia with a normal mental age. At 6 
years of age she developed cogwheel rigidity. 
Repeat ophthalmologic exam and ceruloplas-
min were normal, and CA T scan of the head 
demonstrated mild cerebral atrophy. Electro-
encephalogram was consistent with a meta-
bolic disorder. Leukocyte lysozomal enzymes, 
hepatic sphingomyelinase, and hepatic sphin-
gomyelin were normal. An occult hepatocellu-
lar carcinoma was discovered without evi-
dence of metastases. In November 1981, a 
bone marrow demonstrated foamy histiocytes 
characteristic of Sea-Blue Histiocyte syn-
drome. On 2/24/82, OT 222 underwent 
hepatic transplantation without complications 
save for moderate postoperative hypertension. 
She was discharged 3 weeks posttransplant on 
Cy A and prednisone. 
Nearly 4 months posttransplant her neuro-
logic status has significantly improved. Prior 
to transplant she could not stand indepen-
dently from a chair and could walk short 
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distances only with the aid of a walker. Peg 
board exercises were extremely frustrating. 
Currently, she is walking short distances with-
out the walker, only holding somltOne's hand, 
and is able to get up independently from her 
seat. She can place pegs in the board with 
greater facility. Teachers describe her as hav-
ing more stamina, being more vocal, and 
socially interactive. Current liver enzymes 
and bilirubin are normal. 
OT 202 was an almost 13-year-old boy in a 
gifted class in school when he developed suba-
cute hepatitis diagnosed as Wilson's disease. 
Despite d-penicillamine therapy, he developed 
progressive liver failure. ataxia and cogwheel 
rigidity, gastrointestinal hemorrhage. ascites. 
encephalopathy, and hepatorenal syndrome 
requiring dialysis. On 9/20/81 he underwent 
orthotopic liver transplantation with rapid 
improvement in his sensorium and renal fail-
ure. His hospital course was marked by grad-
ual improvement in his neurologic function, 
although a mild right hemiparesis was noted. 
He had persistently high urinary copper 
excretion (182-434.ug Cu/ g Cr) with normal-
ization of ceruloplasmin (27 mg/dl) by 4 
weeks posttransplant. Penicillamine challenge 
did not significantly increase urine copper 
excretion. Currently, the patient is in his 
regular advanced class in school and has only 
a mild bilateral foot drop as his only neurologic 
residua. Liver function tests are normal on 
Cy A and prednisone. 
DISCUSSION 
Orthotopic liver transplantation for hepat-
ic-based inborn errors of metabolism offers a 
unique opportunity to correct previously often 
fatal disorders. In our 4 patients with AIAT 
deficiency, liver transplantation led to 
assumption of the donor Pi type and/or nor-
malization of the serum AIAT level where 
measured. Two patients were heterozygous 
(MZ, SZ) and assumed a homozygote MM 
state posttransplant. These data confirm simi-
lar information reported by Hood et al.I on 7 
patients who underwent liver transplantation 
with AIAT deficiency. Long-term follow-up 
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of Hood's patients as well as our patients 
reveal no tendency toward reversion to the 
original phenotype, diminution of serum levels 
of AlA T, or development of other complica-
tions of A\AT deficiency.2 It is impossible to 
state, however, if these patients may escape 
complications during longer follow-up. 
Never before has anyone with GSD I been 
able to lead a life with virtually normal glu-
cose hemeostasis. Our patient is the first with 
GSD I treated with liver transplantation. 
Postoperatively she demonstrated clinically 
normal carbohydrate metabolism. More for-
mal testingJ confirmed the clinical impression, 
revealing only minor perturbations of slightly 
prolonged glycemic phase to parenteral gluca-
gon, perhaps reflecting the effect of her low-
dose steroid therapy. While liver transplanta-
tion appears to correct the hepatic-based 
glucose-6-phosphatase deficiency, it perhaps 
should be held in reserve for those patients 
who have failed vigorous medical therapy or 
have developed irreversible and progressive 
liver disease. Also, while the hepatic defect is 
corrected with transplantation, no evidence to 
date exists as to whether other organs affected 
by the enzyme deficiency show any benefit 
from hepatic transplantation. 
Our patient OT 206 with hereditary tyro-
sinemia is the second patient with this disor-
der to be transplanted, and the longest survi-
vor (8 months). Fisch and Starzl4 reported one 
other patient who normalized serum tyrosine 
and urinary metabolites as early as 48 hr 
posttransplant. Their patient died after 3 
months of sepsis and portal vein thrombosis. 
Our patient has no clinical evidence of any 
residual metabolic defect. Ongoing studies, 
however, are continuing to search for such 
defects remaining in other organs, since the 
long-term implications of hepatic transplanta-
tion in tyrosinemia are not known. Perhaps 
with the improved survival of liver transplant 
patients,S it may be warranted to consider 
transplantation prior to the onset of lethal 
complications as malignancy or hepatic fail-
ure. 
The Sea-Blue Histiocyte syndrome is char-
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acterized by the presence of blue, foamy his-
tiocytes in the bone marrow. Patients may 
have progressive neurologic deterioration 
after a period of normal development charac-
terized by ataxia, vertical supranuclear oph-
thalmoplegia, dementia, and often seizures 
along with visceromegaly with an as yet unde-
termined intracellularly stored substance.6 
Our patient had normal liver sphingomyelin 
and normal leukocyte sphingomyelinase activ-
ity, suggesting this disorder may not be a 
variant of Niemann-Pick disease. In addition, 
she did not demonstrate dementia, although it 
may have been early in her clinical course. 
Despite a lack of basic understanding of the 
pathophysiology, it appears that the defect 
may be hepatic-based, and that liver trans-
plantation may have some beneficial effect on 
halting neurologic deterioration, and perhaps 
may reverse neurologic impairment. Much 
work remains to further elucidate this unusual 
problem. 
Neurologic impairment was clearly re-
versed in the patient with Wilson's disease. 
Liver transplantation clearly reversed the 
metabolic defects of copper metabolism as 
well. Groth et al.7 reported 2 teenage boys who 
underwent transplantation for Wilson's dis-
ease. One had neurologic involvement that 
slowly improved over the following 17 months. 
These patients, like ours, demonstrated nor-
malization of serum copper and ceruloplas-
min. Hepatic copper, not yet measured in our 
patient. WaS normal in Groth's 2 patients. It 
appears that liver transplantation may nor-
malize the biochemical abnormalities in Wil-
son's disease, and perhaps more dramatically, 
"~ ... 
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may reverse the neurologic deterioration suf-
fered by these patients. 
Overall, it appears that orthotopic liver 
transplantation may be an effective mode of 
therapy for hepatic-based and often fatal 
inborn errO'rs of metabolism. While underly-
ing metabolic defects may be corrected, long-
term effects of transplantation in these disor-
ders are not known and require further obser-
vation. In addition, with survivors of such 
disorders potentially living to reproductive 
adulthood, genetic counselling becomes in-
creasingly important for these patients and 
their families. 
ADDENDUM 
Since the submission of this manuscript, 
patient OT 222 with the Sea-Blue Histiocyte 
syndrome has had a plateau of neurologic 
improvement II months posttransplant. Sub-
sequent bone marrow examination still dem-
onstrates storage histiocytes and there is evi-
dence of a small amount of storage material in 
the Kupffer cells of the transplanted liver. 
Because Kupffer cells in the transplanted liver 
are of recipient origin, it is not surprising that 
metabolic defects possibly originating in re-
ticuloendothelial cells are not corrected by 
hepatic transplantation. Although the meta-
bolic defect in the Sea-Blue Histiocyte is 
unknown, results in our patient suggest that it 
is not liver-based. 
Patient GT 202 with Wilson's disease has 
continued neurologic improvement with reso-
luti,em of his foot drop 15 months posttrans-
plant. Hepatic copper in the liver homograft is 
normal. 
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